Introduction and Objective: CGM is standard of care for people living with T1D; barriers to sustaining CGM use persist. Less is known about factors leading to non-use following initial CGM uptake.Methods: This qualitative study explored experiences of adults (ages 18-50) with T1D in a CGM uptake randomized controlled trial who received 3 months of CGM supplies. Participants reporting CGM non-use within 12 months of uptake were invited to post-study interviews about their reasons for discontinuation, barriers and facilitators of current device use. Interviews were recorded, transcribed, and analyzed using content analysis.Results: Of 135 participants in the main CGM uptake study, 26% (n=35) reported non-use at 6- or 12-month study timepoints. Nineteen discontinuers attended interviews (age 35±8 years; T1D duration 19±10 years; 84% female; 74% White). Most (n=13; Figure 1) wanted to stay on CGM but couldn’t due to insurance, cost, or processing delays. Planned discontinuation (n=6) was due to data overload, challenges obtaining CGM, or CGM viewed as non-essential given the cost. At the time of interviews, 9 resumed CGM, 5 used AID, and 5 had not readopted CGM. CGM use gaps ranged from 2-22 months.Conclusion: Results highlight the heterogeneity of device pathways and are important to consider when designing CGM education and support. Tailored strategies to address barriers may enable more adults with T1D to benefit from CGM.
M.L. Tanenbaum: None. M.B. Pasmooij: None. E. Iturralde: None. K.K. Hood: Consultant; Sanofi. Advisory Panel; MannKind Corporation. Consultant; Havas Health. Research Support; embecta.
National Institute Of Diabetes And Digestive And Kidney Diseases of the National Institutes of Health (R03DK135840)
Source link
Leave a Reply